Fosun Pharma (600196.SH) controlling subsidiary signs cooperation and option agreement with Clavis Bio.

Zhtng cijng APP xn, fxng yyo (600196.SH) fb gnggo, 2025 nin 12 yu 18 r, gngs kngg zgngs fxng yyo chny y hzufng Clavis Bio qindng "hzu j xunz qun xiy", gnj yudng, y yudng hzu qxin ni, yu fxng yyo chny y Clavis Bio gngtng xundng bidin (jy Clavis Bio tmng) bng tujn zhndu huxun bidin huhw (j hzu xingm) de lnchunqin kif. Clavis Bio ji gi dng hzu xingm xingyu ch zhnggu jngni, xinggng, omn wi de qunqi fnwi ni kif, shngchn j shngyhu dji xk de xunz qun; wln hzufng shfu xngsh shngshu xunz qun, jtun ji gi dng hzu xingm jn xingyu y zhnggu jngni, xinggng, omn dji kif, shngchn j shngyhu de qunl.